Kieron M. Dunleavy, MD, of the National Cancer Institute, discusses the genomic landscape of aggressive lymphomas and how this is informing therapy decisions.
James O. Armitage, MD, of the University of Nebraska Medical Center, discusses how an increased understanding of the biology of lymphomas and their multiple subtypes has had a major impact on the ability to treat patients.
Richard I. Fisher, MD, of Fox Chase Cancer Center-Temple Health, discusses this rare disease––with features between classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma––and reviews the clinical data on treatment.
Wyndham H. Wilson, MD, PhD, of the National Cancer Institute, discusses the molecular underpinnings of diffuse large B-cell lymphoma and targeted treatments.
Steven P. Treon, MD, PhD, of the Dana-Farber Cancer Institute, discusses the question of what is the best upfront therapy for lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia.
Beth M. Faiman, PhD, MSN, CNP, AOCN, of the Cleveland Clinic, discusses working with patients with multiple myeloma to minimize the toxicity of their treatment and improve their outcomes.
